ReviewPharmaceutical research2025
Fucoidan-based Nanomedicine for Hearing Loss: Emerging Roles as Carrier and Therapeutic Agent.
Review in Pharmaceutical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Aspirin in Audiology: A Dual-Edged Sword in Hearing Loss and Its Nanotechnology-Driven Future.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Sensorineural hearing loss (SNHL) poses significant treatment challenges due to the inner ear's complex anatomy and limited regenerative capacity. To overcome these challenges, novel biomaterials with multifunctional therapeutic properties are being explored. However, conventional treatments are often inadequate due to restricted drug penetration and systemic toxicity. Therefore, the aim of this review is to examine the potential of fucoidan-a sulfated polysaccharide derived from brown algae-as both a therapeutic agent and a nanocarrier for targeted drug delivery in the treatment of SNHL. Emphasis is placed on its antioxidant, anti-inflammatory and biocompatible properties, as well as its ability to overcome biological barriers. This review evaluates fucoidan's structural and biological features relevant to otological applications, including its role in modulating signaling pathways (e.g., Notch, Wnt/β-catenin), promoting stem cell homing, and supporting cochlear hair cell regeneration. Fucoidan-based nanoparticles which can be tuned in size from 5 to 900 nm can penetrate the blood-labyrinth barrier, enhance stem cell homing, support cochlear regeneration, and minimize systemic toxicity. Their functionalization with magnetic components allows for localized delivery. Fucoidan shows significant antioxidant and anti-inflammatory effects, promotes mesenchymal stem cell migration, and activates Lgr5 + supporting cells, making it effective in restoring cochlear homeostasis. Fucoidan's multifunctional properties support its development as both a therapeutic agent and drug delivery platform for inner ear disorders. Fucoidan-based nanomedicine represents a promising strategy for next-generation SNHL treatments, although challenges such as variability in molecular composition and delivery barriers require further investigation for clinical translation.
Indexed as
Identifiers
40830728What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.